Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Income from Continuing Operations: 2016-2024

Historic Income from Continuing Operations for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $275.2 million.

  • Protagonist Therapeutics' Income from Continuing Operations fell 18.46% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 73.15%. This contributed to the annual value of $275.2 million for FY2024, which is 448.54% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Income from Continuing Operations of $275.2 million as of FY2024, which was up 448.54% from -$79.0 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Income from Continuing Operations ranged from a high of $275.2 million in FY2024 and a low of -$127.4 million during FY2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$79.0 million (2023), whereas its average is $22.9 million.
  • In the last 5 years, Protagonist Therapeutics' Income from Continuing Operations slumped by 73.81% in 2021 and then spiked by 448.54% in 2024.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Income from Continuing Operations stood at -$72.4 million in 2020, then crashed by 73.81% to -$125.8 million in 2021, then fell by 1.27% to -$127.4 million in 2022, then spiked by 38.02% to -$79.0 million in 2023, then surged by 448.54% to $275.2 million in 2024.